<?xml version='1.0' encoding='utf-8'?>
<document id="22986949"><sentence text="Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study."><entity charOffset="0-9" id="DDI-PubMed.22986949.s1.e0" text="Maraviroc" /></sentence><sentence text="To address the ability of a 24-week Maraviroc (MVC) intensification of a stable antiretroviral therapy (cART) to significantly increase the CD4 cell count slope" /><sentence text="" /><sentence text="Patients were eligible if they had CD4 &lt;350 cells/mm, a CD4 slope &lt;50 cells/mm per year, and sustained plasma HIV-RNA &lt;50 copies/mL over the last 2 years, while receiving a stable cART" /><sentence text=" Patients harboring pure X4-using viruses by a phenotypic tropism assay were excluded" /><sentence text=" MVC was added to cART for 24 weeks, at the recommended dosage per drug-drug interactions" /><sentence text=" The primary endpoint was a significant positive difference in CD4 slopes (with MVC- pre-MVC, paired t test)" /><sentence text="" /><sentence text="Sixty patients (55 men), with median age 51 years, baseline CD4 238 cells/mm, and slope before intensification +14" /><sentence text="1 cells/mm per year were included" /><sentence text=" CD4 nadir was &lt;50/mm in 47% of the population" /><sentence text=" The full set of patients (N = 57) completed week 24, and the on-treatment patients (N = 48) did not discontinue MVC"><entity charOffset="27-28" id="DDI-PubMed.22986949.s12.e0" text="N" /><entity charOffset="85-85" id="DDI-PubMed.22986949.s12.e1" text="N" /><pair ddi="false" e1="DDI-PubMed.22986949.s12.e0" e2="DDI-PubMed.22986949.s12.e0" /><pair ddi="false" e1="DDI-PubMed.22986949.s12.e0" e2="DDI-PubMed.22986949.s12.e1" /></sentence><sentence text=" The median CD4 slope difference from baseline was +22" /><sentence text="6 cells/mm per year (P = 0" /><sentence text="08) in full set and +22" /><sentence text="6 cells/mm per year (P = 0" /><sentence text="04) in on-treatment" /><sentence text=" Slope evolution was not different according to baseline tropism, CD4 nadir, or ongoing cART regimen" /><sentence text=" No drug-related severe adverse events were recorded during intensification"><entity charOffset="1-1" id="DDI-PubMed.22986949.s19.e0" text="N" /></sentence><sentence text=" MVC plasma concentrations were significantly different depending on drug-drug interaction with ongoing cART regimen and tended to be correlated with CD4 cells increase" /><sentence text="" /><sentence text="In this study, MVC intensification of stable cART over 24 weeks was able to enhance CD4 cell slopes in patients with prior insufficient immune restoration despite long-term virological control" /><sentence text="" /></document>